Cognizant Expands Strategic Partnership with Novartis to Transform Global IT Operations using Agentic AI

Date:

Share post:

Cognizant has announced a new five-year, AI-enabled integrated IT operations agreement with Novartis, expanding a strategic relationship that spans more than two decades.

Under the multi-year deal, Cognizant will consolidate Novartis’ applications, infrastructure, cybersecurity, digital workplace, and platform services into a unified, end-to-end operating model. Powered by advanced AI, automation, and agentic capabilities, the transition aims to replace fragmented service delivery and optimize technology performance across Novartis’ global ecosystem.

Cognizant will utilize its engineering-led AI Builder approach and proprietary Cognizant Neuro® AI platform to enable predictive operations, autonomous self-service, full-stack observability, and AI-led software engineering. By streamlining IT complexity and improving user experience, the engagement creates a scalable, future-ready environment to support Novartis’ continued adoption of enterprise AI.

“We are proud to expand our long-standing partnership with Novartis and support its AI-driven transformation across the value chain,” said Manoj Mehta, President EMEA at Cognizant.

Written by: Pragna Biswas

Graphics by: Pramit Hazra

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related articles

Sahajanand Medical Technologies Secures Health Canada Class IV Licence for Supraflex Cruz™️ Stent System, Entering Canadian Market

Sahajanand Medical Technologies (SMT), a leading global medical device company, announced that it has received a Class IV...

Lundbeck Receives U.S. FDA Orphan Drug Designation for Investigational Therapy in Endogenous Cushing’s Syndrome

H. Lundbeck A/S (Lundbeck) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to...

U.S. FDA Grants Accelerated Approval for Bayer’s Sevabertinib as First-Line Therapy in Advanced HER2-Mutant NSCLC Following 75% Response Rate

Bayer announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for sevabertinib, an oral,...

MSD Inaugurates New Technology Centre in Hyderabad to Drive Global Healthcare Innovation and Digital Capabilities

MSD (Merck & Co., Inc.), one of the world's leading global life sciences companies, has officially inaugurated its...